查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1231638

H1N1疫苗的全球市場 2023

H1N1 Vaccines
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 268 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

H1N1疫苗的全球市場到2030年將達到達到32億美元

在COVID-19後改變的商務環境中，2022年22億美元的H1N1疫苗的全球市場，在2022年～2030年間預計將以4.8％增長，2030年之前達到32億美元。本報告所分析的市場區隔之一的肌肉內，年複合成長率將記錄6.2％，到分析期間結束時達到11億美元。考慮疫情後的復甦，鼻腔內給藥市場區隔今後8年的年複合成長率將修正為5％。

美國市場估算為5億8,810萬美元，中國則將以年複合成長率8.7％增長

美國的H1N1疫苗市場在2022年估算為5億8,810萬美元。作為世界第2大經濟大國的中國，在2022年～2030年間預計將以8.7％推移，2030年達到7億3,450萬美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年間預計將各以1.9％和3.5％的速度成長。在歐洲市場中，德國以年複合成長率2.9％成長。

調查對像企業範例

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-6274

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global H1N1 Vaccines Market to Reach $3.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for H1N1 Vaccines estimated at US$2.2 Billion in the year 2022, is projected to reach a revised size of US$3.2 Billion by 2030, growing at aCAGR of 4.8% over the period 2022-2030. Intramuscular, one of the segments analyzed in the report, is projected to record 6.2% CAGR and reach US$1.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Intranasal segment is readjusted to a revised 5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $588.1 Million, While China is Forecast to Grow at 8.7% CAGR

The H1N1 Vaccines market in the U.S. is estimated at US$588.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$734.5 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Select Competitors (Total 33 Featured):

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 17: World H1N1 Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: USA 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Canada 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • JAPAN
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Japan 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • CHINA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: China 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • EUROPE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Europe 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • FRANCE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: France 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • GERMANY
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Germany 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Italy 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • UNITED KINGDOM
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: UK 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Spain 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Russia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • ASIA-PACIFIC
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • AUSTRALIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Australia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • INDIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: India 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 53: South Korea 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • LATIN AMERICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 57: Latin America 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2023 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Latin America 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Argentina 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Brazil 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Mexico 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • MIDDLE EAST
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 69: Middle East 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2023 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Middle East 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 73: Iran 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Israel 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 79: UAE 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030
  • AFRICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Africa 8-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2023 & 2030

IV. COMPETITION